Stick to Your Style<br />By Rev Shark<br />RealMoney.com Contributor<br />12/15/2009 9:11 AM EST <br /><br />Accept the challenges so that you can feel the exhilaration of victory. <br />-- George S. Patton<br /><br />After four quiet but positive days of trading, the major indices are all hovering around their highs of the year. There hasn't been much aggressive action or heavy-duty momentum over the past week of trading but the tone has been upbeat and the buyers are steady and unworried. It is a good example of how stocks are supposed to act during seasonally strong periods. <br /><br />Overall the action looks quite healthy, the major indices aren't too extended and there doesn't seem to be any immediate catalyst for major selling. It is just some good old-fashioned bull market action. <br /><br />So what is the hard trade at this point? Over on RealMoney Silver Doug Kass will occasionally say the hard trade is typically the best trade. In this market he sees the short side as being the more difficult trade. <br /><br />In my view what constitutes the hard trade is a much more subjective matter. It depends a great deal on your style. There are those, like Doug, who are always looking for turning points in the market. For them the easiest trade is to short into strength and buy into weakness. The timing can be quite problematic but the approach can pay off well if you hit the turning points with a little accuracy. <br /><br />This contrary approach to the market is one of Wall Street's favorite games. Just think how many times since March we have heard proclamations that we have seen the highs. And prior to that, when things were melting down, how often did we hear that the lows were in as we kept ticking down steadily? <br /><br />For many market players, calling tops and bottoms is always the easier trade. That is their style and what they are inclined to do. They usually keep on doing it until they get it right. <br /><br />My approach is what is known as trend following. I tend to stick with the trend until I see some good reason not to. Often this can feel like the more difficult thing to do, especially when a trend persists much longer than seems reasonable. Certainly this year the much more difficult trade for many has been to stick with the uptrend even though it often feels like we have run way too far, too fast. <br /><br />The best thing you can do is to know what your style is and embrace it. If you are a trend follower, stick with it until you have reason not to. If you are someone who prefers to look for turning points, keep on doing that as long as it works for you. <br /><br />Right now I see a market that is trending up on a steady flow of good news. The easy trade at times to try to try to predict major turning points, especially if you want to protect gains, but the right trade to make is the one that fits your style. <br /><br />We have a little weakness this morning on slightly soft economic reports, but the focus is going to quickly shift to the FOMC interest rate decision that is due on Wednesday afternoon. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: AIM +23.7%, SNS +5.3%... M&A news: LIMS +42.1% (Abbott to acquire STARLIMS Technologies; this transaction does not impact ABT's previously issued ongoing EPS guidance for 2009)... Select solar stocks showing strength: JASO +3.8% (expects Q4 2009 shipments to exceed prior guidance; issues FY10 shipment guidance; announces a $75 mln share repurchase program), SPWRA +3.0% (provides update of audit committee investigation; says it has made "significant progress in internal investigation"), SOL +2.8%... Other news: ARRY +35.6% (Array BioPharma and Amgen partner in Type 2 Diabetes), WY +12.4% (announces intent to elect REIT status; timing under consideration; to eliminate the company's classified board structure), USEG +11.1% (Brigham Exploration announces Williston 25-36 #1H Bakken well produces at initial rate of ~3,394 BOEPD), ALXA +7.0% (announces submission of AZ-004 NDA), SGEN +6.3% (The Takeda Oncology Company announce strategic collaboration for novel late-stage lymphoma program Brentuximab Vedotin), JAZZ +3.7% (announces it has submitted a New Drug Application to the FDA for JZP-6 for the treatment of fibromyalgia), AMLN +2.0% (Exenatide Once Weekly provided superior glucose control compared to BYETTA in DURATION-5 study), WFC +1.9% (to repay entire $25 bln TARP investment; announces $10.4 bln common stock offering), KONG +1.7% (announces acquisition of Shanghai Dacheng Network), H +1.7% (Abu Dhabi wealth fund takes stake in Hyatt Hotels - Associated Press), ERTS +1.6% (Cramer says this stock is one to buy), HGSI +1.2% (announces submission of marketing authorization application to EMEA for JOULFERON)... Analyst comments: PCS +6.0% (initiated with Outperform at Bernstein), Q +4.2% (upgraded to Buy from Neutral at UBS), ACOM +2.5% (initiated with Buy at Jefferies, initiated with Buy at BofA/Merrill, and initiated with Overweight at Morgan Stanley), LEAP +2.3% (initiated with Outperform at Bernstein), BBT +1.6% (upgraded to Buy at Deutsche), PALM +1.5% (upgraded to Buy at MKM Partners; tgt raised to $20), AVB +0.7% (upgraded to Buy from Neutral at BofA/Merrill). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: RTK -14.6%, BBY -5.2%, PAY -2.5%... Select financial related names showing weakness: AIB -11.3%, ING -5.1%, CS -3.7%, IBN -3.6%, DB -2.8%, HBC -2.7%, ZION -2.6% (initiated with a Sell at UBS), STD -2.2%, C -1.6%, BAC -1.2% (reports Nov trust data)... Select metals/mining names trading lower: RTP -3.3%, GOLD -2.8%, GFI -2.6%, EGO -2.1%, AU -1.9%, VALE -1.5%, BBL -1.4%, BHP -1.3%, NEM -1.2%, GG -1.0%... Select oil/gas names ticking lower: RDS.A -1.8%, BP -1.2%, TOT -1.2%, PBR -1.0%... Other news: GOK -7.0% (priced a 4 mln share common stock offering at $9.25/share), ELN -6.0% (Elan and Transition Therapeutics announce modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease), NVDA -5.1% (still checking), CNO -4.0% (announces a 45 mln share common stock offering), GY -2.2% (Announces $125 Million Private Offering of Convertible Subordinated Debentures)... Analyst comments: HON -2.1% (downgraded to Underweight at HSBC), FHN -2.0% (initiated with a Sell at UBS).